Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, Bangladesh.
Endocrinol Diabetes Metab. 2024 Mar;7(2):e00481. doi: 10.1002/edm2.481.
Elevated liver enzyme levels are suggested to be associated with an increased risk of cardiovascular disease (CVD). However, few studies have explored the relationship between liver enzymes and myocardial infarction (MI). This study aimed to evaluate the potential association of elevated liver enzymes with MI within a population group in Bangladesh.
In this cross-sectional study, 348 participants were enrolled, 189 with MI in the CVD group and 159 in the control group. Serum levels of liver enzymes (AST, ALT and GGT) and other biochemical parameters were measured using standard methods. Multivariate logistic regression models were applied to determine the associations between elevated liver enzymes and CVD.
In the CVD group, 51.6%, 30.9% and 67.7% of individuals had elevated serum AST, ALT and GGT levels, respectively. On the contrary, the control group had 17.0%, 15.1% and 35.2% of individuals with high serum AST, ALT and GGT levels, respectively. Overall, 71.8% of the subjects in the CVD group and 44.7% of the subjects in the control group had at least one or more elevated liver enzymes (p < 0.001). The mean level of all three liver enzymes was significantly higher in the CVD group than in the control group (p < 0.001). In both the CVD and control groups, males had higher levels of liver enzymes than females. In the regression models, the serum levels of AST, ALT and GGT showed a positive and independent association with the prevalence of CVD (p < 0.001). However, GGT showed the strongest association among the three enzymes.
This study shows a high prevalence of liver enzyme abnormalities in individuals with CVD. Serum levels of AST, ALT and GGT were independently associated with the prevalence of CVD. This suggests that measuring liver enzyme levels could be a useful marker in predicting CVD at an early stage.
升高的肝酶水平被认为与心血管疾病（CVD）风险增加有关。然而，很少有研究探讨肝酶与心肌梗死（MI）之间的关系。本研究旨在评估孟加拉国人群中升高的肝酶与 MI 之间的潜在关联。
在这项横断面研究中，共纳入 348 名参与者，其中 189 名在 CVD 组中患有 MI，159 名在对照组中。使用标准方法测量血清肝酶（AST、ALT 和 GGT）和其他生化参数的水平。应用多变量逻辑回归模型来确定升高的肝酶与 CVD 之间的关联。
在 CVD 组中，分别有 51.6%、30.9%和 67.7%的个体血清 AST、ALT 和 GGT 水平升高。相反，对照组中分别有 17.0%、15.1%和 35.2%的个体血清 AST、ALT 和 GGT 水平升高。总体而言，CVD 组中有 71.8%的受试者和对照组中有 44.7%的受试者至少有一种或多种肝酶升高（p<0.001）。CVD 组中所有三种肝酶的平均水平明显高于对照组（p<0.001）。在 CVD 组和对照组中，男性的肝酶水平均高于女性。在回归模型中，AST、ALT 和 GGT 的血清水平与 CVD 的患病率呈正相关且独立相关（p<0.001）。然而，在这三种酶中，GGT 与 CVD 的相关性最强。
本研究表明 CVD 患者中肝酶异常的发生率较高。AST、ALT 和 GGT 的血清水平与 CVD 的患病率独立相关。这表明测量肝酶水平可能是早期预测 CVD 的有用标志物。
